COGTNasdaqPharmaceutical PreparationsUS GAAP · USD

Cogent Biosciences, Inc.

Cogent Biosciences, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing precision medicines for genetically defined diseases. Its lead program is bezuclastinib, which the company is advancing for systemic mastocytosis (SM) and gastrointestinal stromal tumor (GIST), alongside earlier-stage kinase inhibitor programs.

Ask about the company
Operating profit (EBIT)-333m USD
−20.8 %y/y
Net income-329m USD
−28.6 %y/y
Free cash flow-266m USD
−27.7 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-400-300-200-1000100m USD2020: 7.9 m USD2020: EBIT -82 m USD20202021: EBIT -76 m USD20212022: EBIT -148 m USD20222023: EBIT -208 m USD20232024: EBIT -276 m USD20242025: EBIT -333 m USD2025-333
RevenueOperating profit (EBIT)

Business

Share of revenue
Lead clinical asset: bezuclastinib70 %

A precision-medicine kinase inhibitor being developed for SM and GIST, with potential U.S. and select international commercialization.

Other clinical-stage pipeline20 %

Earlier-stage targeted oncology and rare-disease programs including CGT4859, CGT4255, and CGT6297.

Preclinical discovery programs10 %

Internal discovery efforts in JAK2, KRAS, and other undisclosed programs intended to expand the pipeline.

Customers

Cogent does not currently sell approved products, so its near-term 'customers' are primarily patients, physicians, and treatment centers participating in clinical trials. If bezuclastinib is approved, the commercial customer base would be hematologists, oncologists, specialty pharmacies, hospitals, and payors in rare-disease and oncology markets.

Clinical trial patients and investigators

Patients with SM, GIST, and other genetically driven diseases enrolled in trials, and the physicians/sites running those studies.

Hematology and oncology prescribers

Specialists who would prescribe bezuclastinib after approval because the target diseases are managed in specialty care settings.

Specialty pharmacies and hospitals

Distribution and dispensing channels for a future commercial launch, especially for rare-disease and oncology drugs.

Third-party commercialization partners

Potential collaborators that can provide local market access, sales, and distribution capabilities outside the U.S.

Strategy

Cogent's strategy is centered on advancing bezuclastinib through regulatory approval and, if approved, launching it in SM and GIST. The company is also trying to broaden value through pipeline expansion, selective partnerships, and licensing arrangements that can add development capability or geographic reach.

Regulatory approval and launch of bezuclastinibShort term

This is the lead asset and the main path to first product revenue and value creation.

Pipeline expansion beyond bezuclastinibMedium term

A broader pipeline reduces single-asset dependence and supports longer-term growth.

Partnerships and licensingMedium term

External partners can provide local market access, development support, and commercialization scale.

Geography

Cogent is headquartered in the United States and currently conducts most of its business there through R&D, clinical development, and corporate operations. Management has said bezuclastinib could be commercialized in the U.S. and select international markets, with partnerships considered where local expertise or scale is needed.

Risks

Cogent is highly dependent on bezuclastinib, so clinical, regulatory, or commercial setbacks in that program would have an outsized impact. As a pre-revenue biotech, it also faces financing risk, manufacturing and supply-chain dependence, and competition from better-funded companies with similar precision-medicine strategies.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Bezuclastinib development risk1Manufacturing and supply-chain concentration3Regulatory and approval risk4Financing and dilution risk2Competitive pressure5
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Bezuclastinib development riskImpact: CriticalLikelihood: Medium

    The company says its business is highly dependent on the success of bezuclastinib and related trials.

    Exposure: Lead asset for SM and GIST

  2. Financing and dilution riskImpact: HighLikelihood: High

    Cogent has no product revenue and expects to fund operations through equity, debt, and collaborations.

    Exposure: Pre-commercial stage cash burn

  3. Manufacturing and supply-chain concentrationImpact: HighLikelihood: Medium

    API and drug product for bezuclastinib are sourced from single-source suppliers.

    Exposure: Clinical supply and future commercial launch

  4. Regulatory and approval riskImpact: HighLikelihood: Medium

    Approval depends on successful clinical data and FDA/EMA review outcomes.

    ExposureSUMMITPEAKAPEXFuture filings
  5. Competitive pressureImpact: MediumLikelihood: Medium

    Larger pharma and biotech companies may develop safer, more effective, or faster-approved therapies.

    Exposure: Precision medicine and rare-disease oncology

Accounting

Judgemental items
Accrued research and development expenses

Clinical trial and manufacturing costs are estimated before invoices are finalized, affecting quarterly expense timing.

Impact: Can shift reported R&D expense and net loss between periods

Stock-based compensation valuation

The company uses Monte Carlo and probability judgments for awards with market or performance conditions.

Impact: Affects operating expense and equity compensation trends

Going-concern-style funding dependence

The company expects to finance operations through external capital until product revenue begins.

Impact: Dilution, debt covenants, and financing costs may affect future statements

Clinical development cost capitalization

Most development spending is expensed as incurred, so trial progress directly affects earnings.

Impact: R&D intensity remains the main driver of losses

Similar listed companies

Publicly listed companies with a comparable business focus.

Nuvalent, Inc.

Pharmaceutical Preparations

Pliant Therapeutics, Inc

PLRX · Pharmaceutical Preparations

Solid Biosciences Inc.

SLDB · Biological Products, (No Diagnostic Substances)

Sagimet Biosciences Inc.

SGMT · Pharmaceutical Preparations

Mustang Bio, Inc

MBIO · Pharmaceutical Preparations

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

Last updated: 24/09/2026